What's Going On With Biotech Contract Service Firm Catalent Stock Today?
Portfolio Pulse from Vandana Singh
Catalent Inc's (CTLT) shares are trading lower due to its significant exposure to Sarepta Therapeutics Inc (SRPT) following disappointing data from a pivotal gene therapy trial. Sarepta accounted for nearly 10% of total revenue and roughly 30% of non-COVID biologics revenue in fiscal 2023 for Catalent. The company anticipates 30% Y/Y growth in non-COVID biologics revenue for FY24, primarily fueled by a 60%-plus expansion attributed to Sarepta. However, if Sarepta's Elevidys' label expansion falls short of expectations, it could significantly impact Catalent's future.
October 31, 2023 | 7:03 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Catalent's shares are trading lower due to its significant exposure to Sarepta. The company's future could be significantly impacted if Sarepta's Elevidys' label expansion falls short of expectations.
Catalent's stock is trading lower due to its significant exposure to Sarepta, which accounted for a significant portion of its revenue. If Sarepta's Elevidys' label expansion falls short of expectations, it could have significant implications for Catalent's future, potentially impacting its top-line growth and margins.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100
NEGATIVE IMPACT
Sarepta's disappointing data from a pivotal gene therapy trial has led to a drop in Catalent's shares, to which it has significant exposure. Sarepta's future performance could significantly impact Catalent.
Sarepta's disappointing data from a pivotal gene therapy trial has negatively impacted Catalent's shares, to which it has significant exposure. If Sarepta's Elevidys' label expansion falls short of expectations, it could have significant implications for Catalent's future.
CONFIDENCE 80
IMPORTANCE 85
RELEVANCE 80